Maximising Real-World Evidence in Your Pharma Strategy
Real-world evidence (RWE) is now among the most valuable assets in pharma strategy. Clinical trials are the gold standard for proving safety and efficacy, but they cannot answer all commercial, clinical or market access questions. Traditional research is supplemented by real-world evidence, which offers insights into how therapies perform in everyday clinical practice, helping pharma companies to make better-informed decisions throughout the product lifecycle.
The most successful organisations don’t see RWE as something to be collected only after product approval any longer. Instead, they leverage real-world evidence — often through real-world data platforms — across product development, commercialisation and lifecycle management. Timely application of RWE helps companies improve forecasting, strengthen market access, improve patient engagement and support better healthcare outcomes.
Why Real-World Evidence Matters
In healthcare systems, the focus is shifting toward value, lasting results and the experience of the patient. Regulators, payers, healthcare professionals and patients want evidence in addition to clinical trials.
Real-world evidence supports organisations:
Know how good the treatment is
Monitor patient results
Better commercial strategy
Discuss reimbursement increases
Support decisions of regulators
Discover new market opportunities
When combined with market research, competitive intelligence and advanced analytics, RWE provides a more complete view of the healthcare landscape.
In the Early Product Development Phase
Real world evidence should be included well before the end of clinical trials.
In the early stages of development, organisations use RWE to assess:
Burden of disease
Management pathways
Unmet medical needs
Populations of patients
Use of health care resources
Present standards of care
Such insights enable research teams to identify opportunities to align product development with actual healthcare needs.
Supporting the Clinical Development
RWE adds a useful context to the clinical trial data as products move thru clinical development.
RWE can be used by organisations to:
Improve trial design
Choose meaningful endpoints
Enhance patient recruitment
Get a sense of treatment patterns
Group patients into subtypes
Produce evidence of support
Development teams can blend clinical research and practical knowledge to design studies that better reflect routine clinical practice.
Enhancing Market Access
The area where RWE can add the most strategic value is market access.
Payers are increasingly demanding evidence of long term clinical and economic benefit.
Real world data demonstrate:
Economics of health
Cost-effectiveness analyses
Negotiating reimbursement
Value-based healthcare
Studies of healthcare utilisation
Comparative effectiveness studies
Organisations generating high-quality RWE early are better positioned for reimbursement discussions and market access planning.
Better Product Launch Planning
Evidence from the real world is very important before launching a product.
RWE is used by launch teams to:
Verify forecast assumptions
Define target patient populations
Know the prescribing behaviour
Assist commercial messaging
Educate health professionals
Create patient support programs
These insights help organisations to set realistic commercial expectations and improve launch readiness.
Support for Lifecycle Management
The value of real-world evidence is ongoing post-commercialization.
Post-launch RWE helps organisations track:
Safety for the future
Adherence to treatment
Patient’s satisfaction
Use of the product
New indications
Performance comparison
Ongoing evidence generation enables organisations to optimise commercial strategies and identify opportunities to broaden their product lines.
Artificial Intelligence Enhances the Value of RWE
Artificial intelligence is changing the way pharmaceutical companies look at real-world evidence.
AI helps to:
Big data analysis
Recognising patterns
Predictive analysis
Automation in reporting
Identification of risk
Clinical trend analysis
AI doesn’t replace experts; it allows insights teams to analyse more healthcare data, while focusing on strategic interpretation and decision-making.
Creating a Robust Real-World Evidence Strategy
The top pharmaceutical companies embed RWE into enterprise decision-making and do not see it as a stand-alone research activity.
Successful RWE strategies involve:
Planning early
High quality data governance
Collaboration across functions
Evidence generation in progress
Linkage with market research
Continuous performance measurement
Organisations that incorporate RWE into research, medical affairs, commercial strategy, market access, regulatory affairs, and executive leadership make better evidence-based decisions throughout the product lifecycle.
Executive Pharma Insights Conference (EPIC)
The Executive Pharma Insights Conference (EPIC) will unite pharma executives, market researchers, medical affairs leaders, market access specialists, commercial strategists, healthcare professionals, regulators, data scientists and technology innovators to discuss the increasing importance of real-world evidence in the pharmaceutical strategy. At the EPIC Conference, attendees learn how to leverage real-world evidence to apply artificial intelligence, competitive intelligence, forecasting, market research and commercial planning. EPIC Market Research & Insights is a dynamic platform for professionals to share best practices, review successful case studies and discuss innovative approaches to evidence generation that enable better business and healthcare decisions. The Pharma Insights Conference is an opportunity for organisations to network and build their real-world evidence capabilities, preparing them for the future of data-driven pharmaceutical strategy.
Real-world evidence will continue to be at the core of pharmaceutical decision-making as healthcare systems move toward more outcome-, value- and more personalized-based [sic]. Artificial intelligence, digital health technologies, wearables and predictive analytics will create richer evidence to support every stage of the product life cycle.
Organisations that invest in comprehensive RWE strategies, integrate evidence across business functions and continuously evaluate real-world outcomes will be better positioned to improve innovation, strengthen market access, optimise commercialisation and deliver better outcomes for patients.